Close Menu

marketing agreement

Under the terms of the agreement, M3 and G-TAC will promote 14 Pathway tests through G-TAC's personalized medicine platform connected to M3's physician network.

Under the agreement, Genomic Health will make an undisclosed equity investment in Epic Sciences, and will have exclusive rights to market its test in the US.

The agreement covers GynTect, which uses epigenetic biomarkers and methylation-specific PCR to determine if an HPV-positive patient is at risk for developing cervical cancer.

The deal gives SouthGenetics marketing rights for MDxHealth's ConfirmMDx test for prostate cancer in 12 countries, including Mexico, Argentina, and Colombia.

The deal will provide researchers a fully automated solution for immunostaining captured circulating tumor cells deposited on microscope slides.

The deal provides customers a complete end-to-end solution for cytogenomic array and next-generation sequencing services, the firms said.

The partners will co-market the Phenomenex Strata and Strata-X SPE sorbents adapted to Tecan's Freedom EVO series of robotic workstations.

Under the agreement, customers will be able to purchase GeneSeek Genomic Profiler SNP arrays from Illumina, initially for genotyping cattle, pigs, and horses.

Under the terms of the agreement, Tataa will distribute and support Strand's analysis software in Europe and will also use the tool in training programs.

Thermo Fisher will market Horizon's X-MAN human haploid and diploid isogenic cell line collection. 

Pages

NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.

According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.

A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.